Home > Name List By 4 > 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3- ylpyrimidin-2-yl)amino]phenyl]benzamide Canada

CAS No 152459-95-5 , 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-
ylpyrimidin-2-yl)amino]phenyl]benzamide Search by region : Canada

  • Name: 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-
    ylpyrimidin-2-yl)amino]phenyl]benzamide
  • Synonyms: 1xbb; Imatinib free base;4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-
    ylpyrimidin-2-yl)amino]phenyl]benzamide; STI 571; sti-571; STI571; Cgp 57148;152459-95-5; Imatinib Methansulfonate; 1iep;
  • CAS Registry Number:
  • Flash Point: 410.3°C
  • Boiling Point: 754.9°C at 760 mmHg
  • Density: 1.255g/cm3
  • Flash Point: 410.3°C
  • Molecular Weight: 493.60274
  • InchiKey: KTUFNOKKBVMGRW-UHFFFAOYSA-N
  • InChI: InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-
    3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,
    18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)
  • Molecular Formula: C29H31N7O
  • Molecular Structure:CAS No:152459-95-5 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-<br />ylpyrimidin-2-yl)amino]phenyl]benzamide

Related products

Select to

152459-95-5 GLEEVEC

  • Canada TLC PharmaChem., Inc. [Manufacturer]
  • Tel: 905-760-1098
  • Fax: 905-760-2098
  • Address: TLC PharmaChem., Inc.
    5-150 Connie Crescent
    Concord, Ontario
    L4K 1L9, Canada null,nullCanada
Contact Supplier

152459-95-5 IMATINIB

  • Canada Synth?se AptoChem Inc. [Manufacturer]
  • Tel: 514-496-4252
  • Fax: 514-496-4253
  • Address: Synth?se AptoChem Inc.
    6100 Royalmount Ave
    Montreal, QC
    Canada
    H4P 2R2 null,nullCanada
Contact Supplier

Select to

1/1
References of 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-
ylpyrimidin-2-yl)amino]phenyl]benzamide
Title: Imatinib
CAS Registry Number: 152459-95-5
CAS Name: 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide
Synonyms: N-[5-[4-(4-methylpiperazinomethyl)benzoylamido]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidineamine
Molecular Formula: C29H31N7O
Molecular Weight: 493.60
Percent Composition: C 70.57%, H 6.33%, N 19.86%, O 3.24%
Literature References: Tyrosine kinase inhibitor; highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL). Also shown to inhibit the transmembrane receptor KIT and platelet-derived growth factor (PDGF) receptors. Prepn: J. Zimmermann, EP 564409; idem, US 5521184 (1993, 1996 both to Ciba-Geigy); idem et al., Bioorg. Med. Chem. Lett. 7, 187 (1997). Structural mechanism of ABL specificity: T. Schindler et al., Science 289, 1938 (2000). Activity vs KIT and PDGF receptor kinases: E. Buchdunger et al., J. Pharmacol. Exp. Ther. 295, 139 (2000). Clinical trial in CML: H. Kantarjian et al., N. Engl. J. Med. 346, 645 (2002); in gastrointestinal stromal tumors related to KIT: G. D. Demetri et al., ibid. 347, 472 (2002). Review of clinical experience: D. G. Savage, K. H. Antman, ibid. 346, 683-693 (2002); and pharmacology: V. K. Pindolia et al., Pharmacotherapy 22, 1249-1265 (2002); and development of therapeutic target: B. J. Druker, Adv. Cancer Res. 91, 1-30 (2004).
Properties: mp 211-213°. pKa1 8.07; pKa2 3.73; pKa3 2.56; pKa4 1.52.
Melting point: mp 211-213°
pKa: pKa1 8.07; pKa2 3.73; pKa3 2.56; pKa4 1.52
 
Derivative Type: Methanesulfonate
CAS Registry Number: 220127-57-1
Manufacturers' Codes: STI-571; CGP-57148B
Trademarks: Gleevec (Novartis); Glivec (Novartis)
Molecular Formula: C29H31N7O.CH3SO3H
Molecular Weight: 589.71
Percent Composition: C 61.10%, H 5.98%, N 16.63%, O 10.85%, S 5.44%
Literature References: Prepn of crystalline form: J. Zimmermann et al., WO 9903854 (1999 to Novartis).
Properties: Occurs in 2 crystalline modifications. a-form, begins to melt at 226°; b-form, mp 217°. Lipophilic at pH 7.4. Soly in water: >100 g/l (pH 4.2); 49 mg/l (pH 7.4).
Melting point: mp 217°
 
Therap-Cat: Antineoplastic.
Keywords: Antineoplastic; Tyrosine Kinase Inhibitors.